Prior Authorization Required

Prior Authorization is recommended for medical benefit coverage of tocilizumab intravenous products. Approval is recommended for requests that meet the indication-specific criteria and dosing in this policy. Initial approvals require the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated.

• Prior authorization recommended for medical benefit coverage (Actemra, Avtozma, Tofidence) — Tyenne is the preferred biosimilar
• Requests for doses outside established dosing will be considered case-by-case by a clinician
• Initial approval requires specialist prescriber or documented consultation

Indication-specific Prior Authorization Criteria

Coverage is recommended only when indication-specific prior authorization criteria are met. For FDA-approved and supported indications, the request must include documentation of indication-specific requirements (age limits, prior therapy trials, specialist involvement, and response documentation) as detailed in the policy.

• Follow the detailed indication criteria (e.g., rheumatoid arthritis, Castleman disease, VEXAS syndrome, immune checkpoint inhibitor toxicities) including age and diagnosis-specific requirements
• Dosing and dosing intervals per indication must be met (e.g., up to 8 mg/kg with specified maximums and minimum dose intervals)

Prescriber Specialty Requirement

Initial approval requires that the medication be prescribed by or in consultation with an appropriate specialist for the condition being treated. The policy lists examples of required specialties by indication.

• Rheumatology required for rheumatoid arthritis and many inflammatory/autoimmune indications
• Oncology/hematology required for Castleman disease and many malignancy-associated indications
• Transplant center physician/affiliated specialist for transplant-related indications
• Rheumatologist, hematologist, dermatologist, immunologist, or autoinflammatory specialist for VEXAS syndrome
• Specialist involvement must be documented in chart notes or consultation notes at time of request

Required Clinical Response Documentation

Requests must include objective clinical response documentation when required by the indication. Provide baseline and follow-up measures demonstrating benefit or symptom improvement.

• Examples of objective measures: Physician Global Assessment (MD global), Parent/Patient Global Assessment (PGA), JDAS/cJDAS, JSpADA, standardized disease activity scores (CDAI, DAS28-ESR/CRP, RAPID-3, SDAI), and laboratory markers (CRP, ESR)
• Symptom improvement documentation examples: decreased joint pain/tenderness, reduced morning stiffness or fatigue, improved function/ADLs, reduction in fever or rash, normalization or improvement of relevant labs
• Chart notes must document baseline status prior to initiating therapy and subsequent improvement or benefit

Diagnostic Test Requirement

Certain indications require diagnostic testing as part of initial approval. Provide required test results with the prior authorization request.

• VEXAS syndrome: molecular genetic test demonstrating a pathogenic or likely pathogenic UBA1 gene variant is required
• Castleman disease (unicentric): documentation of HIV and HHV8 negative status when applicable
• Other indication-specific lab or diagnostic test requirements as listed in the detailed criteria must be provided

Preferred Product Step Therapy Requirements

A preferred-product step therapy approach applies: Tyenne is the preferred biosimilar product and non-preferred biologics (Actemra, Avtozma, Tofidence) require meeting one of the specified exceptions A–E with chart-note documentation.

• Preferred product: Tyenne. Non-preferred: Actemra, Avtozma, Tofidence
• Step therapy exceptions (one of A–E must be met and documented): A) Patient is not a new start to the non-preferred product (used within prior 365 days); B) Documented allergy to a specific inactive ingredient in all preferred products; C) Documented adverse reaction to a specific inactive ingredient in all preferred products; D) Therapeutic success on the non-preferred product with prior failure of all preferred products during adequate trials (chart notes required); E) Patient diagnosis is included in FDA indications of the non-preferred product but not included for all preferred products
• Patient or prescriber preference and facility/pharmacy stocking issues are not acceptable reasons to bypass step therapy
• An adequate trial is generally considered ≥ 3 months unless otherwise specified or clinically justified

Conventional DMARD Trial Requirement

For rheumatoid arthritis and other indications specifying conventional synthetic DMARD (csDMARD) trials, documentation of at least one adequate csDMARD trial is required unless an exception applies. Exceptions include prior adequate biologic trial documented or contraindication to csDMARDs as specified.

• Examples of conventional DMARDs: methotrexate (oral or injectable), leflunomide, hydroxychloroquine, sulfasalazine
• Rheumatoid arthritis initial therapy generally requires a trial of one csDMARD for at least 3 months, unless the patient has already had a 3-month trial of at least one biologic (in which case stepping back to a csDMARD is not required)
• Chart notes must document duration and response to csDMARD trials or documentation of contraindication/intolerance